Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 102 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT Detects More Lower-Stage CRCs than Usual Care MOST POPULAR ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A... November 12, 2025 EMA Recommends a Change to the Terms of the Marketing Authorisation... October 23, 2025 Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... October 1, 2021 Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... November 21, 2020 Load more HOT NEWS A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy New independent tobacco review sets roadmap for a smokefree England for... Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic...
